A phase I study of CKD-702, an EGFR-cMET bispecific antibody, in advanced or metastatic non-small cell lung cancer (NSCLC)

被引：1
|
作者：
Kim, D-W. [1 ,2 ]
Lee, S-H. [3 ]
Jang, I-J. [4 ]
Park, K-J. [5 ]
Lee, D. H. [6 ]
机构：
[1] Seoul Natl Univ, Coll Med, Dept Internal Med, Seoul, South Korea
[2] Seoul Natl Univ Hosp, Seoul, South Korea
[3] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Dept Med, Seoul, South Korea
[4] Seoul Univ Hosp, Dept Clin Pharmacol & Therapeut, Seoul, South Korea
[5] CKD Chong Kun Dang Res Inst Hyojong, Bio Drug Discovery, Yongin, South Korea
[6] Univ Ulsan, Coll Med, Asan Med Ctr, Dept Oncol, Seoul, South Korea
来源：
ANNALS OF ONCOLOGY | 2022年 / 33卷 / 07期
关键词：
D O I：
10.1016/j.annonc.2022.07.1124
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
998P
引用
收藏
页码：S1010 / S1010
页数：1
相关论文
共 50 条
  • [31] A phase I trial of gefitinib and nimotuzumab in patients with advanced non-small cell lung cancer (NSCLC)
    Kim, Se Hyun
    Shim, Hyo Sup
    Cho, Jaeho
    Jeong, Jae Heon
    Kim, Sun Mi
    Hong, Yun Kyoung
    Sung, Ji Hee
    Ha, Sang-Jun
    Kim, Hye Ryun
    Chang, Hyun
    Kim, Joo Hang
    Tania, Crombet
    Cho, Byoung Chul
    LUNG CANCER, 2013, 79 (03) : 270 - 275
  • [32] A phase I trial of gefitinib and nimotuzumab in patients with advanced non-small cell lung cancer (NSCLC).
    Kim, Han Sang
    Cho, Byoung Chul
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [33] Continuous infusion vinorelbine (VRL) for advanced non-small cell lung cancer (NSCLC). A phase I/III study
    Carbantes, F
    Benavides, M
    Cobo, M
    Hebrero, ML
    Trujillo, R
    Gomez, D
    Breton, JJ
    de la Gandara, I
    Paredes, G
    Juarez, C
    ANNALS OF ONCOLOGY, 1998, 9 : 97 - 97
  • [34] A phase I pharmacokinetic study of bexarotene with paclitaxel and carboplatin in patients with advanced non-small cell lung cancer (NSCLC)
    Jordi Rodon
    Charlotte D. Jacobs
    Quincy Chu
    Eric K. Rowinsky
    Arturo Lopez-Anaya
    Chris H. Takimoto
    Heather A. Wakelee
    Cancer Chemotherapy and Pharmacology, 2012, 69 : 825 - 834
  • [35] Phase I/II study of exisulind and gemcitabine in patients with recurrent advanced non-small cell lung cancer (NSCLC).
    Hoang, T
    Kim, K
    Merchant, J
    Traynor, AM
    Ahuja, HG
    Masters, GA
    McGovern, JD
    Oettel, KR
    Sanchez, FA
    Schiller, JH
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 642S - 642S
  • [36] A phase I study of enzastaurin (Enz) combined with pemetrexed (Pem) in advanced non-small cell lung cancer (NSCLC)
    Takahashi, T.
    Yamamoto, N.
    Murakami, H.
    Ohe, Y.
    Kunitoh, H.
    Nokihara, H.
    Koshiji, M.
    Tamura, T.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [37] A phase I pharmacokinetic study of bexarotene with paclitaxel and carboplatin in patients with advanced non-small cell lung cancer (NSCLC)
    Rodon, Jordi
    Jacobs, Charlotte D.
    Chu, Quincy
    Rowinsky, Eric K.
    Lopez-Anaya, Arturo
    Takimoto, Chris H.
    Wakelee, Heather A.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2012, 69 (03) : 825 - 834
  • [38] Non-small Cell Lung Cancer (NSCLC) Necitumumab in advanced squamous NSCLC approved with EGFR-Expression
    Sankawa, Yuri
    ONCOLOGY RESEARCH AND TREATMENT, 2016, 39 (06) : 395 - 396
  • [39] Phase II study of cetuximab in combination with carboplatin and docetaxel for patients with advanced/metastatic non-small cell lung cancer (NSCLC)
    Belani, C. P.
    Ramalingam, S.
    Schreeder, M.
    Steis, R.
    Guidice, R.
    Marshland, T.
    Butler, B.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [40] Chemotherapy for advanced non-small cell lung cancer (NSCLC)
    Manegold, C
    LUNG CANCER, 2002, 38 : S47 - S50
12345